New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
07:48 EDTLH, MYGNMyriad cancer testing franchise to lose share, says Leerink
Leerink says Horizon Blue Cross Blue Shield's announcement that it is terminating its participation agreements with Myriad Genetics is consistent with its view that the company's core hereditary cancer testing franchise will experience market share and price erosion over time. Leerink notes defenders of Myriad had argued that the company remained in Horizon's network while LabCorp (LH) was the preferred provider, which will no longer be the case. It has a Market Perform rating on Myriad.
News For MYGN;LH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2015
07:41 EDTMYGNMyriad Genetics upgraded on positive risk/reward at Wells Fargo
Subscribe for More Information
06:22 EDTMYGNMyriad Genetics upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information
August 24, 2015
16:17 EDTLHLabCorp: Covance announces agreement with leading pharmaceutical company
Laboratory Corporation of America Holdings announced that Covance Drug Development has received a multi-year award from a leading pharmaceutical company to use Covance's Xcellerate platform as an exclusive central monitoring solution for their worldwide clinical trials portfolio. This landmark agreement with a top-tier pharmaceutical company for Covance's first-in-kind Software-as-a-Service offering reflects the company's unique technology capabilities, and reinforces its position as an industry innovator and leader in clinical informatics solutions.
08:45 EDTLHLabCorp announces availability of VistaSeq Hereditary Cancer Panel
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use